Hepatoprotective effects of chondroitin sulfate and glucosamine sulfate
Background. Long-term use of chondroprotective agents – chondroitin sulfate (CS) and glucosamine sulfate (GS) in the treatment of osteoarthritis puts forward increased requirements for the safety of drugs, primarily in terms of effects on the liver and kidneys.Objective: systematization of data on t...
Main Authors: | I. Yu. Torshin, A. M. Lila, O. A. Gromova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IRBIS LLC
2022-01-01
|
Series: | Фармакоэкономика |
Subjects: | |
Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/630 |
Similar Items
-
Systematic analysis of the molecular pathophysiology of tenosynovitis: promise for using chondroitin sulfate and glucosamine sulfate
by: I. Yu. Torshin, et al.
Published: (2020-04-01) -
Prospects for the use of chondroitin sulfate and glucosamine sulfate with osteoarthritis associated with pathology of the kidneys and urinary system
by: I. Yu. Torshin, et al.
Published: (2020-04-01) -
Molecular mechanisms of myoprotective action of chondroitin sulfate and glucosamine sulfate in sarcopenia
by: O. A. Gromova, et al.
Published: (2019-03-01) -
Perioperative pharmacotherapy for endoprosthetics: potential of chondroitin sulfate and glucosamine sulfate
by: I. Yu. Torshin, et al.
Published: (2022-04-01) -
Prospects for the use of chondroitin sulfate and glucosamine sulfate in the treatment of patients with obesity-associated osteoarthritis (metabolic syndrome)
by: I. Yu. Torshin, et al.
Published: (2022-10-01)